Insmed (NASDAQ: INSM) is one of 290 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Insmed to related companies based on the strength of its valuation, profitability, risk, analyst recommendations, institutional ownership, earnings and dividends.
Valuation & Earnings
This table compares Insmed and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Insmed Competitors||$290.27 million||$35.99 million||63.08|
This table compares Insmed and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
95.3% of Insmed shares are held by institutional investors. Comparatively, 49.4% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 4.0% of Insmed shares are held by insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of current recommendations and price targets for Insmed and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insmed currently has a consensus target price of $37.25, suggesting a potential upside of 23.26%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.40%. Given Insmed’s rivals higher probable upside, analysts plainly believe Insmed has less favorable growth aspects than its rivals.
Risk & Volatility
Insmed has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Insmed’s rivals have a beta of 6.67, meaning that their average stock price is 567% more volatile than the S&P 500.
Insmed rivals beat Insmed on 8 of the 13 factors compared.
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.